SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Red Businesswoman Silhouette, Black Business People Group Team Concept Vector Illustration
Editorial
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top-20 pharma company. Still, there are many prominent women in pharma that could someday break through again.
September 29, 2025
 · 
1 min read
 · 
Annalee Armstrong
GSK CEO Emma Walmsley
C-suite
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Chief Commerical Officer Luke Miels will replace outgoing GSK CEO Emma Walmsley at the U.K. pharma next year.
September 29, 2025
 · 
4 min read
 · 
Annalee Armstrong
Biogen’s headquarters in Massachusetts
Layoffs
Biogen Shuffles 20 Staff After Ending AAV Work
The AAV pullback comes amid Biogen’s aggressive cost-cutting campaign, which put some 1,000 jobs on the chopping block with the goal of generating $1 billion in savings by 2025.
September 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration showing woman starting down curved path with markers toward goal marked by flag
Rare diseases
New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug
Applied Therapeutics has yet to confirm whether the study, posted on Clinicaltrials.gov on Thursday, means it has indeed aligned with the FDA on govorestat’s development.
September 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Mergers & acquisitions
Genmab Buys Rising Cancer Star Merus for $8B
The centerpiece of the acquisition is petosemtamab, Merus’ bispecific antibody targeting EGFR and LGR5, which in May demonstrated best-in-class potential for head-and-neck cancer.
September 29, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA Sign in front of FDA Buildings
FDA
September’s FDA Action Bolsters Keytruda, Ultra-Rare Disease but Deals Two SMA Defeats
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and granted approvals in Barth syndrome and for a subcutaneous version of Merck’s Keytruda that could be key to the blockbuster’s future earnings.
September 29, 2025
 · 
10 min read
 · 
Tristan Manalac
New York, United States - June 18, 2016: New York Stock Exchange with American flags and Wall street sign
FDA
Wall Street the Main Beneficiary of FDA’s Real-Time CRL Disclosures
By publishing complete response letters as soon as they are issued to drug sponsors, the FDA is expanding transparency in a way that, while positioned as a public health measure, also grants investors greater visibility into regulatory decisions. Experts question whether this is the agency’s proper remit.
September 29, 2025
 · 
6 min read
 · 
Ben Hargreaves
Pictured: Scales of justice swing in the air/court
Opinion
Fate of FDA’s Laboratory-Developed Testing Final Rule Hints at Chevron Overturn’s Ramifications
In one of the first demonstrations of the impact of last year’s Loper Supreme Court decision on challenges to agency authority, a judge ruled that the FDA does not have authority to regulate tests developed by clinical laboratories.
September 29, 2025
 · 
4 min read
 · 
Megan Robertson
Pictured: Exterior view of the headquarters of the
Regulatory
6 FDA Decisions To Watch For in Q4
From more than 30 target action dates in the last three months of the year, BioSpace has narrowed the list to six regulatory decisions that could have far-reaching implications for biopharma and patients.
September 29, 2025
 · 
9 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS